To explore the role of Cldn5 involvement in diabetic kidney disease (DKD), its expression was assessed in two mouse models of diabetic nephropathy (DN): a unilateral nephrectomy combined with a streptozotocin (STZ)-induced type 1 diabetes model and the DB/DB type 2 diabetic mouse model. Here, CLDN5 is linked to liver dysplastic nodule.